Publications by authors named "Yobiga Thevakumaran"
Importance: There is a growing interest in understanding whether cardiovascular magnetic resonance (CMR) myocardial tissue characterization helps identify risk of cancer therapy-related cardiac dysfunction (CTRCD).
Objective: To describe changes in CMR tissue biomarkers during breast cancer therapy and their association with CTRCD.
Design, Setting, And Participants: This was a prospective, multicenter, cohort study of women with ERBB2 (formerly HER2)-positive breast cancer (stages I-III) who were scheduled to receive anthracycline and trastuzumab therapy with/without adjuvant radiotherapy and surgery.
Background: Echocardiographic global longitudinal strain (GLS) is a useful measure for detection of cancer treatment-related cardiac dysfunction (CTRCD) but is influenced by blood pressure changes. This limitation may be overcome by assessment of myocardial work (MW), which incorporates blood pressure into the calculation.
Objectives: This work aims to determine whether myocardial work indices (MWIs) can help diagnose or prognosticate CTRCD.
Article Synopsis
- The study focuses on diagnosing cancer therapy-related cardiac dysfunction (CTRCD) in women with HER2-positive early-stage breast cancer, emphasizing the challenges faced in using cardiovascular magnetic resonance (CMR) for consistent assessment due to limited access to repeated scans.
- Researchers aimed to create a diagnostic model that combines echocardiographic left ventricular ejection fraction (LVEF), strain measurements, and biomarker levels, using CMR as the gold standard for validation.
- Out of 160 recruited patients, 136 completed the study, and CMR identified CTRCD in 27% of them; various echocardiographic measures and biomarkers were analyzed to improve the accuracy of diagnosing CTRCD.
Objectives: This study sought to compare the prognostic value of cardiovascular magnetic resonance (CMR) and 2-dimensional echocardiography (2DE) derived left ventricular (LV) strain, volumes, and ejection fraction for cancer therapy-related cardiac dysfunction (CTRCD) in women with early stage breast cancer.
Background: There are limited comparative data on the association of CMR and 2DE derived strain, volumes, and LVEF with CTRCD.
Methods: A total of 125 prospectively recruited women with HER2+ early stage breast cancer receiving sequential anthracycline/trastuzumab underwent 5 serial CMR and 6 of 2DE studies before and during treatment.